Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

412 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The puzzling situation of hospital exemption for advanced therapy medicinal products in Europe and stakeholders' concerns.
Cuende N, Boniface C, Bravery C, Forte M, Giordano R, Hildebrandt M, Izeta A, Dominici M; Legal and Regulatory Affairs Committee—Europe, International Society for Cellular Therapy. Cuende N, et al. Among authors: hildebrandt m. Cytotherapy. 2014 Dec;16(12):1597-600. doi: 10.1016/j.jcyt.2014.08.007. Epub 2014 Oct 5. Cytotherapy. 2014. PMID: 25293816 Free article. No abstract available.
Regulation of advanced therapy medicinal products in Europe and the role of academia.
Pearce KF, Hildebrandt M, Greinix H, Scheding S, Koehl U, Worel N, Apperley J, Edinger M, Hauser A, Mischak-Weissinger E, Dickinson AM, Lowdell MW. Pearce KF, et al. Among authors: hildebrandt m. Cytotherapy. 2014 Mar;16(3):289-97. doi: 10.1016/j.jcyt.2013.08.003. Epub 2013 Oct 8. Cytotherapy. 2014. PMID: 24113428 Review.
Immunotherapy: opportunities, risks and future perspectives.
Hildebrandt M, Peggs K, Uharek L, Bollard CM, Heslop HE. Hildebrandt M, et al. Cytotherapy. 2014 Apr;16(4 Suppl):S120-9. doi: 10.1016/j.jcyt.2014.02.001. Cytotherapy. 2014. PMID: 24629797 Free PMC article. Review.
Development of cell therapy medicinal products by academic institutes.
de Wilde S, Guchelaar HJ, Herberts C, Lowdell M, Hildebrandt M, Zandvliet M, Meij P. de Wilde S, et al. Among authors: hildebrandt m. Drug Discov Today. 2016 Aug;21(8):1206-12. doi: 10.1016/j.drudis.2016.04.016. Epub 2016 Apr 23. Drug Discov Today. 2016. PMID: 27117349
Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies-the German Cancer Consortium approach.
Krackhardt AM, Anliker B, Hildebrandt M, Bachmann M, Eichmüller SB, Nettelbeck DM, Renner M, Uharek L, Willimsky G, Schmitt M, Wels WS, Schüssler-Lenz M. Krackhardt AM, et al. Among authors: hildebrandt m. Cancer Immunol Immunother. 2018 Apr;67(4):513-523. doi: 10.1007/s00262-018-2119-y. Epub 2018 Jan 29. Cancer Immunol Immunother. 2018. PMID: 29380009 Free PMC article. Review.
Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study.
Kokowski K, Stangl S, Seier S, Hildebrandt M, Vaupel P, Multhoff G. Kokowski K, et al. Among authors: hildebrandt m. Strahlenther Onkol. 2019 Apr;195(4):352-361. doi: 10.1007/s00066-019-01434-9. Epub 2019 Feb 11. Strahlenther Onkol. 2019. PMID: 30747241 Free PMC article. Clinical Trial.
412 results